Athina Papadopoulou

List of Publications by Year
in descending order

36	694	623574	580701
papers	citations	14	25
		h-index	g-index

36	36	36	1313
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal. Multiple Sclerosis and Related Disorders, 2022, 59, 103681.	0.9	11
2	Optical coherence tomography quantifies peripapillary edema and response to treatment in idiopathic intracranial hypertension: description of two cases. Nervenheilkunde, 2022, , .	0.0	0
3	The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. Neurology, 2022, 99, .	1.5	21
4	Standardization and digitization of clinical data in multiple sclerosis. Nature Reviews Neurology, 2021, 17, 119-125.	4.9	8
5	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. Human Brain Mapping, 2021, 42, 2399-2415.	1.9	10
6	Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
7	Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort. European Journal of Neurology, 2021, 28, 4153-4166.	1.7	10
8	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. NeuroImage: Clinical, 2021, 30, 102608.	1.4	9
9	Isolated oculomotor palsy due to acute ischemic midbrain stroke. Acta Neurologica Belgica, 2020, 120, 479-481.	0.5	1
10	Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. Multiple Sclerosis Journal, 2020, 26, 993-996.	1.4	6
11	Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. Acta Neurologica Belgica, 2020, 120, 223-225.	0.5	11
12	Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study. Brain Imaging and Behavior, 2020, 14, 2159-2175.	1.1	6
13	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 46, 102579.	0.9	14
14	Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results. Journal of Neurology, 2020, 267, 1744-1753.	1.8	5
15	Longitudinal patterns of cortical thinning in multiple sclerosis. Human Brain Mapping, 2020, 41, 2198-2215.	1.9	26
16	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. Multiple Sclerosis and Related Disorders, 2020, 41, 102027.	0.9	11
17	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. Journal of Neurology, 2020, 267, 1536-1546.	1.8	35
18	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurology, The, 2020, 19, 336-347.	4.9	90

#	Article	IF	Citations
19	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1156-1164.	0.9	20
20	Damage of the lateral geniculate nucleus in MS. Neurology, 2019, 92, e2240-e2249.	1.5	29
21	Association of clinical headache features with stroke location: An MRI voxel-based symptom lesion mapping study. Cephalalgia, 2018, 38, 283-291.	1.8	14
22	Unilateral leg oedema due to spontaneous Achilles tendon rupture. Oxford Medical Case Reports, 2018, 2018, omy022.	0.2	0
23	Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study. Multiple Sclerosis Journal, 2017, 23, 597-603.	1.4	66
24	Tracking the Evolution of Cerebral Gadolinium–Enhancing Lesions to Persistent T1 Black Holes in Multiple Sclerosis: Validation of a Semiautomated Pipeline. Journal of Neuroimaging, 2017, 27, 469-475.	1.0	5
25	Daclizumab for the treatment of multiple sclerosis. Neurodegenerative Disease Management, 2017, 7, 279-297.	1.2	2
26	Superior Effects of High-Intensity Interval Training vs. Moderate Continuous Training on Arterial Stiffness in Episodic Migraine: A Randomized Controlled Trial. Frontiers in Physiology, 2017, 8, 1086.	1.3	28
27	Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy. Acta Neurologica Belgica, 2015, 115, 445-447.	0.5	1
28	Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2015, 14, 749-759.	1.0	15
29	Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 322-330.	1.4	8
30	Intrathecal Gadolinium for Magnetic Resonance Myelography in Spontaneous Intracranial Hypotension: Valuable But May Be Risky–Reply. JAMA Neurology, 2014, 71, 802.	4.5	0
31	MRI characteristics of periaqueductal lesions in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 542-551.	0.9	13
32	Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1290-1296.	1.4	103
33	Detection of Cerebrospinal Fluid Leaks by Intrathecal Contrast-Enhanced Magnetic Resonance Myelography. JAMA Neurology, 2013, 70, 1576-7.	4.5	3
34	Teriflunomide for oral therapy in multiple sclerosis. Expert Review of Clinical Pharmacology, 2012, 5, 617-628.	1.3	18
35	Evolution of MS lesions to black holes under DNA vaccine treatment. Journal of Neurology, 2012, 259, 1375-1382.	1.8	15
36	Dimethyl fumarate for multiple sclerosis. Expert Opinion on Investigational Drugs, 2010, 19, 1603-1612.	1.9	51